NIH Closes Clinical Trial Assessing Eli Lilly Antibody Treatment For Hospitalized COVID-19 Patients Due To Lack Of Clinical Benefit

The Hill: NIH halts study of Eli Lilly antibody drug for treating hospitalized COVID-19 patients
“Federal researchers have ended a study into the effectiveness of Eli Lilly’s antibody treatment for hospitalized COVID-19 patients due to a lack of effectiveness. The National Institute of Allergy and Infectious Diseases (NIAID), which is funding the study, announced late Monday that an independent monitoring board found little clinical benefit in the treatment and recommended that it be stopped. The study had been paused earlier this month due to a potential safety issue, but the NIAID said the monitoring board’s decision was driven by lack of clinical benefit…” (Weixel, 10/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.